LOS ANGELES, May 19, 2025/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company, announced positive topline results from its Phase 1b/2a diSArm trial. The study evaluated AP-SA02, an intravenous multi-phage therapeutic, for the treatment of Staphylococcus aureus bacteremia in the intent-to-treat population. The trial, a multicenter, randomized, double-blind, placebo-controlled study, assessed the safety, tolerability, and efficacy of AP-SA02 in addition to best available antibiotic therapy versus antibiotic therapy alone. No treatment-related serious adverse events were observed. Armata has developed a proprietary manufacturing process capable of producing over 10,000 full courses of phage therapy annually at its California facility. The company plans to move towards a pivotal trial to further evaluate AP-SA02.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。